Blackstone Inc. is investing as quite a bit as $250 million in U.Okay. biotechnology agency Autolus Therapeutics PLC to fund the last word ranges of enchancment of a model new treatment to cope with a crucial kind of leukemia, the companies talked about.
Of the entire funding, as quite a bit as $150 million will help the occasion and commercialization of obecabtagene autoleucel, a cell treatment that targets a scenario known as acute lymphoblastic leukemia. London-based Autolus will get hold of $50 million of that upfront, with the rest to be paid as the company achieves positive milestones. In return, Blackstone’s life-sciences unit will get hold of a portion of the treatment’s royalties.
https://www.wsj.com/articles/blackstone-to-invest-up-to-250-million-in-autolus-therapeutics-of-u-k-11636336822?mod=rss_markets_main | Blackstone to Make investments As a lot as $250 Million in Autolus Therapeutics of U.Okay.
